Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council's 10th AML trial (MRC AML10)

Blood

Volumn 89, Issue 7, 1997, Pages 2311-2318

  Hann, Ian M ^a,b   Stevens, Richard F ^a   Goldstone, Anthony H ^a   Rees, John K H ^a   Wheatley, Keith ^a   Gray, Richard G ^a   Burnett, Alan K ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROCORTISONE; METHOTREXATE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0030895252     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.7.2311     Document Type: Article

References (15)

1. Stalfelt AM: Quality of life during induction treatment of acute myeloid leukaemia. A comparison of three intensive chemotherapy regimens using three instruments of quality of life assessment. Acta Oncol 33:477, 1994
2. Goldie JH, Goldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67:923, 1983
3. Lampkin BC, Woods WG, Buckley JD: Preliminary results of intensive therapy of children and adolescents with acute non-lymphocytic leukaemia - A CCG report. Haematol Bluttransfus 33:923, 1990
4. Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, Versteeg C, Hammond GD: Impact of high dose cytarabine and asparaginase intensification on childhood acute myeloid leukaemia: a report from the CCG. J Clin Oncol 11:538, 1993
5. Rees JKH, Gray RG, Wheatley K: Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. Br J Haematol 94:89, 1996
6. Hardy JR, Pinkerton CR: Cancer chemotherapy and mechanisms of resistance, in Plowman PN, Pinkerton CR (eds): Paediatric Oncology, Clinical-Practice and Controversies London, UK, Chapman and Hall, 1992, p 87
7. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351, 1989
8. Zwelling LA: Topoisomerase II as a target of anti-leukaemia drugs: A review of controversial areas. Hematol Pathol 3:101, 1989
9. Odom LF, Gordon EM: Acute monoblastic leukaemia in infancy and early childhood: Successful treatment with an epipodophyllotoxin. Blood 64:875, 1984
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias (FAB cooperative group). Br J Haematol 33:451, 1976
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
12. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F III, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre OR: Comparison of three remission induction regimens and two post induction strategies for the treatment of acute non-lymphocytic leukaemia: A Cancer and Leukaemia Group B Study. Blood 69:1441, 1987
13. Bishop JF, Lowenthal RM, Joshua D, Matthew JP, Todd D, Cobcroft R, Whiteside MG, Kronemberg H, Ma D, Dodds A, Herrman R, Szer J, Wolf NN, Young G: Etoposide in acute non-lymphocytic leukaemia. Blood 75:27, 1990
14. McKenna RW, Bloomfield CD, Dick F, Nesbit ME, Brunning RD: Acute monoblastic leukaemia: Diagnosis and treatment of ten cases. Blood 46:481, 1975
15. Ritter J, Creutzig U, Schellong G: Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: Results of the German Childhood AML Studies BFM-78 and BFM-83, in Büchner, Schellong, Hiddemann, Urbanitz, Ritter (eds): Haematology and Blood Transfusion. Acute Leukaemias II. Berlin, Germany, Springer-Verlag, 1990, p 185